A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
Termination reason: On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.
Inclusion Criteria:
Exclusion Criteria: